1. US Food and Drug Administration. Early communication about an ongoing safety review of montelukast (Singulair). 2008. https://wayback.archive-it.org/7993/20170112033551/http:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070618.htm.
2. US Food and Drug Administration. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). 2009. https://wayback.archive-it.org/7993/20170111080414/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165489.htm.
3. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Medicines Safety Update. Montelukast - neuropsychiatric risks. 2013. https://www.tga.gov.au/sites/default/files/msu-2013-02.pdf.
4. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions. 2019. https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions.
5. Joint Formulary Committee. British National Formulary. https://bnf.nice.org.uk/.